2023 World Conference on Lung Cancer (Posters)-P2.16. Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial

P2.16. Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial - PDF(Abstract)

Back to course

Pdf Summary

The PEERS trial is a phase II clinical trial investigating the efficacy and safety of a combination treatment for extensive-stage small cell lung cancer (ES-SCLC). The treatment includes lenvatinib, pembrolizumab, and chemotherapy. Lenvatinib is a potent inhibitor of multiple receptors involved in cancer growth, and pembrolizumab is an immune checkpoint inhibitor. The trial aims to improve survival outcomes and explore novel combination strategies for ES-SCLC.<br /><br />The trial consists of two parts: a safety run-in and a phase 2 expansion. The safety run-in included six patients, and no dose-limiting toxicities were reported. The phase 2 expansion aims to recruit a total of 85 patients and has already started with eight patients initiating treatment.<br /><br />In the trial, patients receive chemotherapy along with pembrolizumab and lenvatinib. After four cycles of induction treatment, patients with partial or complete response may receive prophylactic cranial irradiation. The maintenance phase includes pembrolizumab for up to 31 additional cycles and lenvatinib at a dose of 20 mg daily. Treatment continues until disease progression or unacceptable toxicity.<br /><br />The primary endpoint of the trial is progression-free survival, while secondary endpoints include overall response rate, overall survival, and safety of the combination treatment. Additionally, molecular biomarkers will be investigated.<br /><br />The combination of lenvatinib, pembrolizumab, and chemotherapy shows promising activity in various tumor types, and this trial aims to evaluate its efficacy in ES-SCLC. By inhibiting multiple pathways involved in cancer growth and stimulating the immune response, the combination treatment has the potential to improve outcomes for patients with ES-SCLC. The trial is ongoing, and further results and analyses are awaited to determine the effectiveness and safety of this treatment approach.

Asset Subtitle

Noemí Reguart Aransay

Meta Tag

Speaker Noemí Reguart Aransay

Topic SCLC & Neuroendocrine Tumors: Trials in Progress

Keywords

PEERS trial

ES-SCLC

lenvatinib

pembrolizumab

chemotherapy

combination treatment

progression-free survival

overall response rate

overall survival

molecular biomarkers